Skip to content

Effects of jelly containing lactic acid bacteria on protection against infection and immune function in elderly people

Effects of jelly containing lactic acid bacteria on protection against infection and immune function in elderly people - Effects of jelly containing lactic acid bacteria on protection against infection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000009252
Enrollment
20
Registered
2012-11-05
Start date
2012-11-05
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

common cold, infectious disease

Interventions

Jelly containing lactic acid bacteria, one cup per day, for 12 weeks Placebo Jelly, one cup per day, for 12 weeks

Sponsors

Fukushimura Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Elderly individuals living in nursing care center, who are scheduled to receive influenza vaccination.

Exclusion criteria

Exclusion criteria: 1) Individuals severely affected with hepatic dysfunction, renal dysfunction, cardiovascular disorder, respiratory dysfunction, endocrine disorder, metabolic disorder, intestinal obstruction, cancer and dyslipidemia. 2) Individuals with allergy to soybean, peach and gelatin, which are contained in the tested foods. 3) Individuals daily consuming supplements of lactic acid bacteria except those provided by meals. 4) Other individuals judged as inappropriate for the study by the physician in charge.

Design outcomes

Primary

MeasureTime frame
Incidence, number of subjects and duration regarding symptoms of common cold (nose, throat, fever, pain) and infectious disease such as influenza virus infection.

Secondary

MeasureTime frame
NK cell activity, neutrophil phagocytic activity, neutrophil bactericidal activity, antibody titers in response to the vaccine, immunoglobulin, salivary sIgA and composition of intestinal microbiota.

Countries

Japan

Contacts

Public ContactHiroyasu Akatsu

Fukushimura Hospital Choju Medical Institute

0532-46-7511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026